Inhibits TRKA, TRKB and TRKC, ROS1 and ALK kinase activity, suppressing oncogenic signalling in tumours driven by NTRK gene fusions or ROS1 rearrangements.
Indications / reported uses
Treatment of adults and paediatric patients with solid tumours harbouring an NTRK gene fusion, when disease is metastatic or surgery is likely to cause severe morbidity and there is no satisfactory alternative therapy or progression following treatment
Treatment of adults with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) under the applicable product label
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Entrectinib Environmental Risk Assessment (ERA) (the Entrectinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.